Clinical data in DLBCLs with low versus high MT-I and MT-II expression in the tumor cells
. | Low expression, less than 20% . | High expression, more than 20% . |
|---|---|---|
| Age, y (no. patients) | 64.2 (97) | 65.4 (18) |
| Stage (no. patients) | 2.58 (73) | 2.65 (17) |
| IPI (no. patients) | 2.31 (59) | 2.40 (15) |
| 5-year overall survival, % (no. patients) | 40.7 (97) | 12.0 (18) |
. | Low expression, less than 20% . | High expression, more than 20% . |
|---|---|---|
| Age, y (no. patients) | 64.2 (97) | 65.4 (18) |
| Stage (no. patients) | 2.58 (73) | 2.65 (17) |
| IPI (no. patients) | 2.31 (59) | 2.40 (15) |
| 5-year overall survival, % (no. patients) | 40.7 (97) | 12.0 (18) |